Company intelligence / Profile preview

Tandem Pharmaceuticals

San Diego, California, United Statesng.linkedin.com ↗

Ownership: Private
Employees: ~2000
Development stage: Other

Overview

Tandem Diabetes Care has commercialized advanced automated insulin delivery systems powered by proprietary algorithms such as Control-IQ and Basal-IQ. Their latest pivotal study with Control-IQ+ in type 2 diabetes showed positive outcomes published in NEJM. The company’s products are widely adopted and have demonstrated improved glycemic control and patient quality of life in real-world settings.

Therapeutic areas: Endocrinology
Modalities: DeviceSoftware/Application (connected health)
Industry: Therapeutic Medical Devices

Partnerships

Collaborations with continuous glucose monitoring companies (e.g., Dexcom) [inferred from industry context]

Beyond the preview

Go deeper on Tandem Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tandem Pharmaceuticals.

Explore the full profile